Biotech | December 05, 2021
SPARC to licence Biomodifying’s IP
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
The fund aims at investing in companies that extends human healthspan
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes, as per WHO
One of the very few facilities in India to have this capability, marking a remarkable feat in LifeCell’s expedition to take genome sequencing to the next level in India
The country’s top heart transplant surgeon Dr. K.R Balakrishnan to be leading the programme for Jaslok
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
According to a survey conducted by FOGSI last year, 92% of the doctors opined that anaemia due to iron deficiency can be eradicated in five years
Records the largest number of videos of people saying the same sentence uploaded to Facebook in one hour to raise awareness on Iron Deficiency Anaemia
Subscribe To Our Newsletter & Stay Updated
